Innovative Cardiovascular Solutions said today that it closed an $8 million Series C round of financing to support clinical trials of its Emblok embolic protection system as well as manufacturing and operational activities.
The Kalamazoo, Mich.-based company’s Emblok system is an embolic protection device designed for full circumferential aortic collection while protecting the cerebral, abdominal and peripheral vasculature from embolic debris.
The system is designed for use in transcatheter aortic valve replacement and structural heart procedures and includes an integrated 4 French radiopaque pigtail catheter to provide constant visualization and eliminate the need for dye injections to confirm positioning, Innovative Cardiovascular Solutions said.
“We are pleased with the continued support from our current investors as we advance the clinical evaluation of the Emblok system. Our team has made significant progress refining the system’s design and preparing for the U.S. pivotal trial. We are in discussions with the U.S. Food and Drug Administration to finalize the pivotal trial design and look forward to demonstrating the Emblok system’s clinical impact during structural heart procedures,” co-founder & CEO R. Plemmons said in a press release.
Last July, Innovative Cardiovascular Solutions said that it raised $5 million in an oversubscribed Series B round of financing to support its Emblok embolic protection system.